已收盤 11-20 16:00:00 美东时间
-0.050
-1.31%
今日重点评级关注:富瑞:维持ArriVent BioPharma"买入"评级,目标价从18美元升至30美元;古根海姆:维持第一太阳能"买入"评级,目标价从282美元升至299美元
10-28 12:30
Needham analyst Gil Blum downgrades Artiva Biotherapeutics (NASDAQ:ARTV) from Buy to Hold.
10-28 00:55
Company halting further development of AlloNK® (AB-101), including the planned phase 3 pivotal trial Updated deep B cell depletion and clinical response data is consistent with previously reported findings; however, updated longer-term data showed that durability of clinical response did not meet ...
10-27 19:34
今日重点评级关注:Truist Securities:维持Inventiva"买入"评级,目标价从13美元升至18美元;富瑞:维持Sagimet Biosciences"买入"评级,目标价从25美元升至26美元
10-05 16:26
Oral presentation includes safety and efficacy data as of the July 2, 2026 data cutoff, highlighting clinically meaningful improvements in disease activity and symptoms at six months in 11 patients with longstanding, highly active Sjögren disease Mean stimulated salivary flow increased from 0.4 to 1...
10-01 19:32
今日重点评级关注:Ascendiant Capital:维持IGC Pharma"买入"评级,目标价从5.25美元升至5.5美元;Ascendiant Capital:维持Lucid Diagnostics"买入"评级,目标价从9美元升至9.25美元
06-09 11:33
Multiple EULAR presentations reinforce potential of AlloNK to drive deep B-cell depletion and meaningful clinical responses across refractory rheumatoid arthritis, Sjögren disease and systemic
06-08 18:34
Abstracts:LB0003Oral PresentationAB-101, an Outpatient-Administered Allogeneic NK Cell Therapy Combined with Rituximab, Generates Robust Clinical Efficacy Responses Comparable with Autologous CAR T in 31 Patients with
05-20 04:07
Market News Updates News Commentary Breakthrough immunotherapies, ADCs, and precision oncology platforms continue driving major investor attention across the global cancer treatment sector ...
05-14 21:00
今日重点评级关注:Needham:维持Artiva Biotherapeutics"买入"评级,目标价从18美元升至41美元;HC Wainwright & Co.:维持SAB Biotherapeutics"买入"评级,目标价从7美元升至10美元
05-13 11:46